Advertisement
Advertisement
QNCX
Quince Therapeutics, Inc. Common Stock
32.73
USDSponsored
+2.08
+6.79%
Aug 11, 15:59 UTC -4
Closed
After-Market
31.72
-1.01
-3.09%
QNCX Earnings Reports
Positive Surprise Ratio
QNCX beat 10 of 22 last estimates.
45%
Next Report
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$1.43
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/-97.14%
Quince Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 10, 2026, QNCX reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -18.23 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.
Looking ahead to Q3 26, 5 analysts forecast an EPS of -1.43 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Imunon, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.94
Actual
-$0.54
Surprise
+42.83%
Dermata Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.56
Actual
-$0.74
Surprise
-31.91%
Apogee Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.13
Surprise
-4.39%
Legend Biotech Corporation - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.07
Actual
$0.09
Surprise
+17.80%
Mineralys Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.54
Actual
-$2.85
Surprise
-422.26%
Bicara Therapeutics Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.84
Actual
-$0.82
Surprise
+3.18%
Autolus Therapeutics plc - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.22
Actual
-$0.15
Surprise
+31.82%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.01
Actual
$0.05
Surprise
+400.00%
LENZ Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.02
Surprise
+6.95%
Codexis, Inc.
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+7.67%
FAQ
What were Quince Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Quince Therapeutics, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to Quince Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Quince Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Quince Therapeutics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Quince Therapeutics, Inc. Common Stock is expected to report EPS of -$1.43 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement